Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285865
3.
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Future Oncol
; 20(9): 493-505, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882449
4.
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.
World J Urol
; 41(8): 2021-2031, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029329
5.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261050
6.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724226
7.
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate
; 82(13): 1237-1247, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675470
8.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
9.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med
; 20(1): 112, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35331214
10.
Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities.
Curr Opin Urol
; 32(5): 462-465, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849697
11.
Modern paradigms for prostate cancer detection and management.
Med J Aust
; 217(8): 424-433, 2022 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183329
12.
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(27): 2979-2986, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950899
13.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Future Oncol
; 18(4): 425-436, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080190
14.
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(10): 1185-1198, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034502
15.
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Intern Med J
; 52(8): 1339-1346, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33710759
16.
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Prostate
; 81(13): 992-1001, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34254334
17.
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
J Urol
; 205(5): 1361-1371, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356529
18.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028967
19.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
BJU Int
; 128(3): 331-342, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33682320
20.
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
BJU Int
; 128 Suppl 1: 18-26, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622543